Ascendis Pharma A/S
F:A71
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ascendis Pharma A/S
F:A71
|
DK |
|
Centerspace
NYSE:CSR
|
US |
|
Vaxart Inc
NASDAQ:VXRT
|
US |
|
E
|
East Japan Railway Co
SWB:EJR
|
JP |
|
W
|
Walmart Inc
F:WMT
|
US |
|
R
|
Ring Energy Inc
F:KWE1
|
US |
|
TotalEnergies SE
LSE:TTE
|
FR |
|
W
|
Wuling Motors Holdings Ltd
OTC:WLMTF
|
HK |
|
M
|
MTN Group Ltd
XBER:LL6
|
ZA |
|
E
|
Exelon Corp
XMUN:PEO
|
US |
|
Ageas SA
MIL:1AGS
|
BE |
|
P
|
Premium Group Co Ltd
OTC:PMMFF
|
JP |
|
S
|
SAP SE
XMUN:SAP
|
DE |
|
D
|
DigitalOcean Holdings Inc
XMUN:0SU
|
US |
|
Industrias Penoles SAB de CV
F:4FO
|
MX |
|
Acme United Corp
F:UT1
|
US |
|
I
|
Infineon Technologies AG
SWB:IFX
|
DE |
Ascendis Pharma A/S
Ascendis Pharma is a biopharmaceutical company that develops and sells medicines for rare endocrine diseases. Its main products are long-acting treatments built with its TransCon technology, which is designed to release medicine slowly so patients do not need frequent dosing. The company sells these drugs to specialty pharmacies, hospitals, doctors, and the payers that cover treatment for patients with chronic hormone disorders. The company makes money mainly from selling approved medicines and, in some cases, from partnerships around its drug technology. Its best-known products treat conditions such as growth hormone deficiency in children and hypoparathyroidism in adults. That means Ascendis is not a broad drugmaker; it focuses on a small set of hard-to-treat diseases where easier dosing can matter a lot to patients and doctors. What sets Ascendis apart is that it tries to turn short-lived hormone or protein medicines into longer-acting versions. This can improve convenience and may help patients stay on therapy, which is especially important in rare diseases that need lifelong treatment. In simple terms, Ascendis sits between drug discovery and specialty care, using its own drug-delivery platform to create and commercialize niche medicines.
Ascendis Pharma is a biopharmaceutical company that develops and sells medicines for rare endocrine diseases. Its main products are long-acting treatments built with its TransCon technology, which is designed to release medicine slowly so patients do not need frequent dosing. The company sells these drugs to specialty pharmacies, hospitals, doctors, and the payers that cover treatment for patients with chronic hormone disorders.
The company makes money mainly from selling approved medicines and, in some cases, from partnerships around its drug technology. Its best-known products treat conditions such as growth hormone deficiency in children and hypoparathyroidism in adults. That means Ascendis is not a broad drugmaker; it focuses on a small set of hard-to-treat diseases where easier dosing can matter a lot to patients and doctors.
What sets Ascendis apart is that it tries to turn short-lived hormone or protein medicines into longer-acting versions. This can improve convenience and may help patients stay on therapy, which is especially important in rare diseases that need lifelong treatment. In simple terms, Ascendis sits between drug discovery and specialty care, using its own drug-delivery platform to create and commercialize niche medicines.
Revenue growth: Ascendis said Q1 was an inflection point, with total revenue of EUR 247 million and strong underlying demand across its endocrine portfolio, despite one-time noise in YORVIPATH and channel inventory drawdown in SKYTROFA.
YORVIPATH demand: Global YORVIPATH revenue was EUR 197 million, with more than 1,000 new U.S. patients prescribed in the quarter and more than 6,300 patients prescribed in total by the end of March.
YUVIWEL launch: YUVIWEL was commercially available in early April and has already been prescribed for more than 60 children by more than 35 health care providers, with management saying early demand is encouraging.
Profitability: The company posted operating profit of EUR 25 million and non-IFRS operating profit of EUR 55 million, and said it expects operating margins to improve as revenue scales.
Balance sheet moves: Ascendis completed a direct listing on NASDAQ, redeemed all outstanding convertible senior notes in May, and agreed to sell its PRV for USD 187.5 million in cash.
Pipeline focus: Management said it will discontinue internal oncology development of TransCon IL-2 beta gamma and focus capital on endocrine growth opportunities and other TransCon programs.
